Prognostic impact of statin use in patients with heart failure and preserved ejection fraction

Circulation Journal : Official Journal of the Japanese Circulation Society
Kotaro NochiokaCHART-2 Investigators

Abstract

The effectiveness of statins remains to be examined in patients with heart failure (HF) with preserved ejection fraction (EF). METHODS AND RESULTS: Among 4,544 consecutive HF patients registered in the Chronic Heart Failure Registry and Analysis in the Tohoku district-2 (CHART-2) between 2006 and 2010, 3,124 had EF ≥50% (HFpEF; mean age 69 years; male 65%) and 1,420 had EF <50% (HF with reduced EF (HFrEF); mean age 67 years; male 75%). The median follow-up was 3.4 years. The 3-year mortality in HFpEF patients was lower in patients receiving statins [8.7% vs. 14.5%, adjusted hazard ratio (HR) 0.74; 95% confidence interval (CI), 0.58-0.94; P<0.001], which was confirmed in the propensity score-matched cohort (HR, 0.72; 95% CI, 0.49-0.99; P=0.044). The inverse probability of treatment weighted further confirmed that statin use was associated with reduced incidence of all-cause death (HR, 0.71; 95% CI, 0.62-0.82, P<0.001) and noncardiovascular death (HR, 0.53; 95% CI, 0.43-0.66, P<0.001), specifically reduction of sudden death (HR, 0.59; 95% CI, 0.36-0.98, P=0.041) and infection death (HR, 0.53; 95% CI, 0.35-0.77, P=0.001) in HFpEF. In the HFrEF cohort, statin use was not associated with mortality (HR, 0.87; 95% CI, 0.73-1.04, P=0.1...Continue Reading

References

Dec 23, 1971·The New England Journal of Medicine·P A McKeeW B Kannel
Jun 25, 2003·International Journal of Cardiology·Meral KayikciogluHakan Kultursay
Mar 12, 2004·Journal of the American College of Cardiology·Karen HoggJohn McMurray
Jun 17, 2004·Circulation·Jean Davignon
Apr 13, 2005·Circulation·Sabine SteinerChristoph W Kopp
Aug 9, 2005·Intensive Care Medicine·Rafael FernandezAntonio Artigas
Jul 1, 2006·Thorax·E M W van de GardeH G M Leufkens
Jul 21, 2006·The New England Journal of Medicine·Theophilus E OwanMargaret M Redfield
Sep 12, 2006·European Heart Journal·John G F ClelandUNKNOWN PEP-CHF Investigators
Apr 5, 2007·JAMA : the Journal of the American Medical Association·Rajesh GuptaNeil R Powe
Jun 29, 2007·Current Medical Research and Opinion·Craig I ColemanC Michael White
Aug 21, 2007·Journal of the American College of Cardiology·Gregg C FonarowUNKNOWN OPTIMIZE-HF Investigators and Hospitals
Nov 7, 2007·The New England Journal of Medicine·John KjekshusUNKNOWN CORONA Group
Nov 27, 2007·The American Journal of Cardiology·Giacomo LevantesiRoberto Marchioli
Dec 25, 2007·European Heart Journal·Christophe TribouilloyZiad Massy
Oct 14, 2009·Archives of Internal Medicine·Imad M TleyjehTalal Ibrahim
Feb 16, 2010·Journal of the American College of Cardiology·Walter J Paulus, Joris J M van Ballegoij
Jul 6, 2010·European Journal of Heart Failure·Dulcenombre Gómez-GarreArturo Fernández-Cruz
Mar 26, 2011·Circulation Journal : Official Journal of the Japanese Circulation Society·Nobuyuki ShibaUNKNOWN CHART-2 Investigators
Feb 3, 2012·European Journal of Heart Failure·Masanobu MiuraUNKNOWN CHART-2 Investigators
Dec 15, 2012·Circulation·Alan S GoUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Mar 19, 2013·Circulation Journal : Official Journal of the Japanese Circulation Society·Hiroyuki TakanoUNKNOWN PEARL Study Investigators
Apr 24, 2013·European Journal of Heart Failure·Michelle M Y Chan, Carolyn S P Lam
May 4, 2013·Arteriosclerosis, Thrombosis, and Vascular Biology·Shin-ichi TanakaHiroaki Shimokawa
Jun 12, 2013·Journal of the American College of Cardiology·Clyde W YancyUNKNOWN American Heart Association Task Force on Practice Guidelines
Jul 3, 2013·Circulation Journal : Official Journal of the Japanese Circulation Society·Kotaro NochiokaUNKNOWN CHART-2 Investigators
Aug 21, 2013·Circulation Journal : Official Journal of the Japanese Circulation Society·Yasuhiko Sakata, Hiroaki Shimokawa
Dec 10, 2013·Circulation Journal : Official Journal of the Japanese Circulation Society·Yasuhiko SakataHiroaki Shimokawa

❮ Previous
Next ❯

Citations

Sep 12, 2015·Circulation Journal : Official Journal of the Japanese Circulation Society·Ryoichi UshigomeUNKNOWN CHART-2 Investigators
Oct 7, 2015·Circulation Journal : Official Journal of the Japanese Circulation Society·Osamu Tsukamoto, Masafumi Kitakaze
Jun 2, 2015·Circulation Journal : Official Journal of the Japanese Circulation Society·Osamu Tsukamoto, Masafumi Kitakaze
Jul 30, 2015·European Journal of Heart Failure·Hiroaki ShimokawaYasuhiko Sakata
Oct 28, 2016·Circulation Journal : Official Journal of the Japanese Circulation Society·Hiroya MizunoYasushi Sakata
Mar 6, 2018·Circulation Journal : Official Journal of the Japanese Circulation Society·Kyoung Im ChoKwang Kon Koh
Sep 1, 2018·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Joseph C GodoyAlice E Zemljic-Harpf
Dec 25, 2015·Circulation Journal : Official Journal of the Japanese Circulation Society·Tsuyoshi Nozue
May 31, 2019·Heart Failure Reviews·Antonis S ManolisHelen Melita
Nov 2, 2019·Lipids in Health and Disease·Agata Bielecka-DabrowaMaciej Banach
Mar 10, 2015·Circulation Journal : Official Journal of the Japanese Circulation Society·Nobuyuki Ohte, William C Little
Jun 16, 2018·European Heart Journal·Carolyn S P LamDirk J van Veldhuisen
Feb 1, 2017·American Journal of Lifestyle Medicine·Lindsey CiliaWen-Chih Wu
Apr 12, 2019·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Muaamar Al-GobariNathalie Thilly
Jul 11, 2020·Current Cardiology Reports·Daria M AdamczakEwa Straburzyńska-Migaj
Apr 15, 2019·Current Treatment Options in Cardiovascular Medicine·Daniel N Silverman, Sanjiv J Shah
Jan 30, 2016·Circulation Journal : Official Journal of the Japanese Circulation Society·Hayato Matsushima, Naohisa Hosomi
Mar 20, 2016·American Journal of Physiology. Heart and Circulatory Physiology·Patrícia G RodriguesInês Falcão-Pires
Nov 13, 2018·Circulation Journal : Official Journal of the Japanese Circulation Society·Kyohei MarumeToshihisa Anzai

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.